Seventy-five percent of bladder cancers are non-muscle invasive. The treatment strategy includes the transurethral resection of bladder tumor (TURB) followed by intravesical immunotherapy with the bacillus of Calmette-Guerin (BCG) or chemotherapy, depending on the grade of bladder tumor. Despite a proper BCG intravesical instillations schedule, up to 40% of patients present a failure within 2 years. The aim of this retrospective study was to investigate the predictive factors in the response to BCG in patients with a high-grade non-muscle invasive bladder cancer diagnosis.
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer / M. Ferro, B. Barone, F. Crocetto, G. Lucarelli, G.M. Busetto, F. Del Giudice, M. Maggi, F. Crocerossa, F. Cantiello, R. Damiano, M. Borghesi, P.L. Bove, R. Papalia, A. Mari, S. Luzzago, F. Soria, M. Marchioni, E. La Civita, D. Terracciano, F.A. Mistretta, M. Piccinelli, A. Marmiroli, G.I. Russo, L. Schips, R. Hurle, R. Contieri, S. Perdonà, P. Del Prete, V. Mirone, O.S. Tataru, G. Musi, E. Montanari, O. de Cobelli, M.D. Vartolomei. - In: UROLOGIC ONCOLOGY. - ISSN 1873-2496. - (2022). [Epub ahead of print] [10.1016/j.urolonc.2022.05.016]
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer
S. Luzzago;F.A. Mistretta;M. Piccinelli;A. Marmiroli;G. Musi;E. Montanari;O. de Cobelli;
2022
Abstract
Seventy-five percent of bladder cancers are non-muscle invasive. The treatment strategy includes the transurethral resection of bladder tumor (TURB) followed by intravesical immunotherapy with the bacillus of Calmette-Guerin (BCG) or chemotherapy, depending on the grade of bladder tumor. Despite a proper BCG intravesical instillations schedule, up to 40% of patients present a failure within 2 years. The aim of this retrospective study was to investigate the predictive factors in the response to BCG in patients with a high-grade non-muscle invasive bladder cancer diagnosis.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S1078143922001867-main.pdf
solo utenti autorizzati
Tipologia:
Publisher's version/PDF
Dimensione
628.75 kB
Formato
Adobe PDF
|
628.75 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
